Novartis will close its Longmont, Colorado biomanufacturing after over anticipating the amount of capacity needed to produce Zolgensma and other gene therapies. When Novartis acquired AveXis in May 2018, it quickly began expanding its manufacturing network to support the then lead candidate Zolgensma (onasemnogene abeparvovec-xioi1). By the time the gene therapy won US approval as a treatment for spinal muscular atrophy (SMA) in May the following year, Novartis was confident it had built up a sufficient production footprint for launch…

Boehringer Ingelheim invested in capacity at sites in Germany and Austria last year on the back of high capacity utilization and increased demand for CDMO services. While most of Boehringer Ingelheim’s revenues come from its own portfolio of human and animal therapeutics, Boehringer Ingelheim’s biopharma contract manufacturing business pulled in €837 million ($986 million) in 2020, up 6.6% on the year prior. According to the firm’s annual report, “Boehringer Ingelheim covers the entire biopharmaceutical value chain, from development of the…